Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zofran Patent Ruling

This article was originally published in The Pink Sheet Daily

Executive Summary

Two method-of-use patents for GlaxoSmithKline's Zofran are valid and infringed by Teva's ANDA, Wilmington, Del. federal Judge Gregory Sleet ruled Aug. 20

You may also be interested in...



Teva Gains First Generic Zofran Injection Approval

FDA approval comes roughly one month ahead of patent expiration for GSK's injectable antiemetic.

Teva Gains First Generic Zofran Injection Approval

FDA approval comes roughly one month ahead of patent expiration for GSK's injectable antiemetic.

Express Scripts Anticipates Growth In 2005 From Zithromax, Zofran Generics

PBM cites anticipated contribution to growth from several first-time generics that could enter the market in 2005. Nevertheless, Express Scripts concedes that generic utilization growth will be weaker in 2005 than in other years. Subsidiary CuraScript will aid PBM's growth by converting clients that use an outside specialty pharmacy provider.

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel